Analyst Yi Chen of H.C. Wainwright reiterated a Buy rating on Alpha Tau Medical Ltd (DRTS – Research Report), with a price target of $9.00.
Yi Chen’s rating is based on Alpha Tau Medical Ltd.’s promising clinical and regulatory developments expected in 2025. The company plans to initiate several significant clinical trials, including treating the first brain cancer patient in Israel and enrolling the first patient in a pancreatic cancer pilot study in the U.S. Additionally, they aim to seek FDA IDE approval for a study in glioblastoma multiforme patients and expect a response from Japan’s PMDA for pre-market approval for Alpha DaRT in head and neck cancer. These upcoming milestones indicate potential growth and advancements in their medical treatments.
Moreover, Alpha Tau Medical Ltd. has reported positive interim results in their ongoing trials. Notably, the combination of Alpha DaRT with Keytruda showed a significant improvement in response rates for head and neck cancer patients compared to Keytruda alone. Furthermore, the trials in pancreatic cancer demonstrated a high disease control rate and favorable overall survival outcomes. These promising results suggest that Alpha DaRT could be an effective treatment option, supporting the Buy rating given by Yi Chen.
According to TipRanks, Chen is an analyst with an average return of -15.3% and a 30.45% success rate. Chen covers the Healthcare sector, focusing on stocks such as Opko Health, OKYO Pharma Limited Sponsored ADR, and Veru.
In another report released on March 13, Piper Sandler also reiterated a Buy rating on the stock with a $5.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com